Abstract Objective: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC).…
Abstract Background: Cannabidiol has been shown to be effective in seizure reduction in patients with Dravet syndrome, Lennox–Gastaut syndrome, and…
Abstract Objective: Controlled and open label trials have demonstrated efficacy of cannabidiol for certain epileptic encephalopathies. However, plant derived cannabidiol…
Abstract Background: The interest in cannabidiol (CBD) for treatment of epilepsy has been increasing over the last years. However, practitioner’s…